Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Recruiting

Phase 3

Inotuzumab Ozogamicin & ChemotherapyInotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

Sponsor:

Alliance for Clinical Trials in Oncology

Code:

NCT03150693

Conditions

B Acute Lymphoblastic Leukemia

Eligibility Criteria

Sex: All

Age: 18 - 39

Healthy Volunteers: Not accepted

Interventions

Allopurinol

Cytarabine

Daunorubicin Hydrochloride

Vincristine Sulfate

Dexamethasone

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-29. This information was provided to ClinicalTrials.gov by Alliance for Clinical Trials in Oncology on 2026-04-27.